期刊
JOURNAL OF INFECTIOUS DISEASES
卷 200, 期 4, 页码 624-628出版社
OXFORD UNIV PRESS INC
DOI: 10.1086/600892
关键词
-
资金
- NCRR NIH HHS [KL2 RR025746, KL2RR025746] Funding Source: Medline
- NIAID NIH HHS [5 T32 AI07151-29, T32 AI007151, R21 AI076785-01A1, 1R21AI076785, R21 AI076785] Funding Source: Medline
Most trials of antimalarials occur in areas in which reinfections are possible. For Plasmodium falciparum, reinfections are distinguished from recrudescences by polymerase chain reaction analysis of 3 polymorphic genes. However, the validity of this approach has never been rigorously tested. We tested for misclassification in 6 patients from clinical trials in Thailand and Cambodia who were classified as being reinfected by the standard polymerase chain reaction protocol. Using heteroduplex tracking assays and direct DNA sequencing, we found that 5 (83%) of 6 patients were misclassified. Misclassification in this manner overestimates the efficacy of antimalarials and delays the recognition of decreasing therapeutic efficacy, thus delaying potential changes in policy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据